Liquidia TPIP PAH Clinical Trial Data 2024

Presentation of interim clinical trial data for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension. The 16-week randomized study evaluated safety, tolerability, oxygenation, 6-minute walk distance, cardiac biomarkers, lung function, and quality of life outcomes. Data disclosed May 9, 2024, includes efficacy and safety analyses from ongoing development.